VYGR · Voyager Therapeutics, Inc. · Executive Compensation
Market Cap
$196.56M
Shares
61.62M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Alfred Sandrock | M.D., Ph.D. Chief Executive Officer, President, and Director | $2,508,370 |
| Jacquelyn Fahey Sandell | Former Chief Legal Officer | $1,474,986 |
| Robin Swartz | Chief Business Officer & Chief Operating Officer | $1,454,300 |
| Toby Ferguson | M.D., Ph.D. Former Chief Medical Officer | $1,364,420 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Alfred Sandrock | M.D., Ph.D. Chief Executive Officer, President, and Director | $3,379,876 |
| Toby Ferguson | M.D., Ph.D. Former Chief Medical Officer | $2,966,797 |
| Robin Swartz | Chief Business Officer & Chief Operating Officer | $1,613,804 |
| Jacquelyn Fahey Sandell | Former Chief Legal Officer | $1,232,309 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Amy Quinlan | principal accounting officer | Appointed | 2026-04-21 |
| Robin Swartz | principal financial officer and treasurer | Appointed | 2026-04-21 |
| Nathan Jorgensen, Ph.D. | Chief Financial Officer | Resigned | 2026-04-21 |
| Toby Ferguson, M.D., Ph.D. | Chief Medical Officer | Resigned | 2026-02-12 |
| George Scangos, Ph.D. | Class I director | Appointed | 2025-06-05 |
| Catherine J. Mackey, Ph.D. | Class I director | Appointed | 2025-06-05 |
| Glenn Pierce, M.D., Ph.D. | Class I director | Appointed | 2025-06-05 |
| Grace E. Colón, Ph.D. | Class I director | Appointed | 2025-06-05 |
Key facts
CIK
1640266
CUSIP
92915B106
13F (30d)
70 filings
70 filers
Visit website
Investor relations